Trial Profile
TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 09 Apr 2020 According to a Pfizer media release, this study is planned to be initiated later this week and is supported by a Pfizer grant.
- 06 Apr 2020 New trial record